Download PDF
Nuklearmedizin 2022; 61(03): 273-279
DOI: 10.1055/a-1650-9995
Review

Alpha emitting nuclides in nuclear medicine theranostics

Alpha emittierende Nuklide für nuklearmedizinische Theranostik
Matthias Miederer
1   Department of Nuclear Medicine, University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany (Ringgold ID: RIN39068)
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Theranostic applications with radio-isotopes currently are rapidly progressing and expand nuclear medicine application in clinical routine. Alpha emitting isotopes, in particular, have long been hypothesized to achieve relevant advances for the treatment of malignancies. Here, an overview of their properties and the knowledge of radiobiology is reviewed in view of clinical translation. Clinical evidence of radiopharmaceuticals based on alpha emitters is summarized with a focus on recent developments for treatment of metastasized castration resistant prostate cancer.

Zusammenfassung

Theranostische Anwendungen mit Radioisotopen machen derzeit rasche Fortschritte und erweitern den Einsatz der Nuklearmedizin in der klinischen Routine. Insbesondere alpha-emittierenden Isotopen werden seit Langem deutliche Fortschritte bei der Behandlung bösartiger Erkrankungen zugetraut. Hier wird ein Überblick über ihre Eigenschaften und die Erkenntnisse der Radiobiologie im Hinblick auf klinische Anwendung gegeben. Die aktuellen klinischen Erfahrungen mit Radiopharmazeutika auf der Basis von Alpha-Emittern werden zusammengefasst, wobei der Schwerpunkt auf den jüngsten Entwicklungen zur Behandlung von metastasiertem kastrationsresistentem Prostatakrebs liegt.

Schlüsselwörter

hoher LET - PSMA - alpha-Strahler

Keywords

high LET - PSMA - alpha emitter


Publication History

Received: 08 September 2021

Accepted: 15 September 2021

Article published online:
08 October 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Macklis RM, Lin JY, Beresford B, Atcher RW, Hines JJ, Humm JL. Cellular kinetics, dosimetry, and radiobiology of alpha-particle radioimmunotherapy: induction of apoptosis. Radiat Res 1992; 130 (02) 220-6
    CrossrefPubMedSearch in Google Scholar
  • 2 Parker C, Nilsson S, Heinrich D, Helle SI, OʼSullivan JM, Fossa SD. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369 (03) 213-23
    Search in Google Scholar
  • 3 Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS. et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019; 20 (03) 408-19
    CrossrefPubMedSearch in Google Scholar
  • 4 Feuerecker B, Tauber R, Knorr K, Heck M, Beheshti A, Seidl C. et al. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA. Eur Urol 2021; 79 (03) 343-350
    CrossrefPubMedSearch in Google Scholar
  • 5 Miederer M, McDevitt MR, Borchardt P, Bergman I, Kramer K, Cheung NK. et al. Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2. Clin Cancer Res 2004; 10 (20) 6985-6992
    CrossrefPubMedSearch in Google Scholar
  • 6 Miederer M, Thomas C, Beck J, Hampel C, Krieger C, Baque PE. et al. Haematopoietic toxicity of radium-223 in patients with high skeletal tumour burden. Nuklearmedizin 2015; 54 (05) 197-203
    Thieme ConnectPubMedSearch in Google Scholar
  • 7 Deandreis D, Maillard A, Zerdoud S, Bournaud C, Vija L, Sajous C. et al. RADTHYR: an open-label, single-arm, prospective multicenter phase II trial of Radium-223 for the treatment of bone metastases from radioactive iodine refractory differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2021;
    CrossrefPubMedSearch in Google Scholar
  • 8 Schulte TL, Nekolla EA, Wick RR. Long-term investigation of the risk of malignant diseases following intravenous radium-224 treatment for ankylosing spondylitis. Strahlenther Onkol 2009; 185 (09) 549-556
    CrossrefPubMedSearch in Google Scholar
  • 9 Khreish F, Ebert N, Ries M, Maus S, Rosar F, Bohnenberger H. et al. (225)Ac-PSMA-617/(177)Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. Eur J Nucl Med Mol Imaging 2020; 47 (03) 721-728
    CrossrefPubMedSearch in Google Scholar
  • 10 Sartor AO, la Fougere C, Essler M, Ezziddin S, Kramer G, Elllinger J. et al. Lutetium-177-prostate-specific membrane antigen ligand following radium-223 treatment in men with bone-metastatic castration-resistant prostate cancer: real-world clinical experience. J Nucl Med 2021;
    CrossrefPubMedSearch in Google Scholar
  • 11 McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P, Frank RK. et al. Tumor therapy with targeted atomic nanogenerators. Science 2001; 294: 1537-1540
    CrossrefPubMedSearch in Google Scholar
  • 12 Mease RC, Kang C, Kumar V, Ray S, Minn IL, Brummet M. et al. An improved (211)At-labeled agent for PSMA-targeted alpha therapy. J Nucl Med 2021;
    CrossrefPubMedSearch in Google Scholar
  • 13 Ramdahl T, Bonge-Hansen HT, Ryan OB, Larsen S, Herstad G, Sandberg M. et al. An efficient chelator for complexation of thorium-227. Bioorg Med Chem Lett 2016; 26 (17) 4318-4321
    CrossrefPubMedSearch in Google Scholar
  • 14 Eychenne R, Cherel M, Haddad F, Guerard F, Gestin JF. Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight". Pharmaceutics 2021; 13 (06)
    CrossrefPubMedSearch in Google Scholar
  • 15 Pouget JP, Constanzo J. Revisiting the Radiobiology of Targeted Alpha Therapy. Front Med (Lausanne) 2021; 8: 692436
    CrossrefPubMedSearch in Google Scholar
  • 16 Chan HS, de Blois E, Morgenstern A, Bruchertseifer F, de Jong M, Breeman W. et al. In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy. PLoS One 2017; 12 (07) e0181473
    CrossrefPubMedSearch in Google Scholar
  • 17 Graf F, Fahrer J, Maus S, Morgenstern A, Bruchertseifer F, Venkatachalam S. et al. DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy. PLoS One 2014; 9 (02) e88239
    CrossrefPubMedSearch in Google Scholar
  • 18 Bannik K, Madas B, Jarzombek M, Sutter A, Siemeister G, Mumberg D. et al. Radiobiological effects of the alpha emitter Ra-223 on tumor cells. Sci Rep 2019; 9 (01) 18489
    CrossrefPubMedSearch in Google Scholar
  • 19 Sgouros G. Dosimetry, Radiobiology and Synthetic Lethality: Radiopharmaceutical Therapy (RPT) With Alpha-Particle-Emitters. Semin Nucl Med 2020; 50 (02) 124-132
    CrossrefPubMedSearch in Google Scholar
  • 20 Basaco T, Pektor S, Bermudez JM, Meneses N, Heller M, Galvan JA. et al. Evaluation of Radiolabeled Girentuximab In Vitro and In Vivo. Pharmaceuticals (Basel) 2018; 11 (04)
    CrossrefPubMedSearch in Google Scholar
  • 21 Drecoll E, Gaertner FC, Miederer M, Blechert B, Vallon M, Muller JM. et al. Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cells. PLoS One 2009; 4 (05) e5715
    CrossrefPubMedSearch in Google Scholar
  • 22 Miederer M, Henriksen G, Alke A, Mossbrugger I, Quintanilla-Martinez L, Senekowitsch-Schmidtke R. et al. Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors. Clin Cancer Res 2008; 14 (11) 3555-3561
    CrossrefPubMedSearch in Google Scholar
  • 23 Jurcic JG. Targeted Alpha-Particle Therapy for Hematologic Malignancies. Semin Nucl Med 2020; 50 (02) 152-161
    CrossrefPubMedSearch in Google Scholar
  • 24 Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR. et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002; 100 (04) 1233-1239
    CrossrefPubMedSearch in Google Scholar
  • 25 Hatcher-Lamarre JL, Sanders VA, Rahman M, Cutler CS, Francesconi LC. Alpha emitting nuclides for targeted therapy. Nucl Med Biol 2021; 92: 228-240
    CrossrefPubMedSearch in Google Scholar
  • 26 Pfannkuchen N, Bausbacher N, Pektor S, Miederer M, Rosch F. In vivo Evaluation of [(225)Ac]Ac-DOTA(ZOL) for alpha-Therapy of Bone Metastases. Curr Radiopharm 2018; 11 (03) 223-230
    CrossrefPubMedSearch in Google Scholar
  • 27 Beyer GJ, Miederer M, Vranjes-Duric S, Comor JJ, Kunzi G, Hartley O. et al. Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using 149Tb-rituximab. Eur J Nucl Med Mol Imaging 2004; 31 (04) 547-554
    CrossrefPubMedSearch in Google Scholar
  • 28 Dizdarevic S, Petersen PM, Essler M, Versari A, Bourre JC, la Fougere C. et al. Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice. Eur J Nucl Med Mol Imaging 2019; 46 (05) 1102-1110
    CrossrefPubMedSearch in Google Scholar
  • 29 Jadvar H, Colletti PM. Targeted alpha-therapy in non-prostate malignancies. Eur J Nucl Med Mol Imaging 2021;
    CrossrefPubMedSearch in Google Scholar
  • 30 Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas KS. et al. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res 2010; 16 (21) 5303-5311
    CrossrefPubMedSearch in Google Scholar
  • 31 Linden O, Bates AT, Cunningham D, Hindorf C, Larsson E, Cleton A. et al. Thorium-227-Labeled Anti-CD22 Antibody (BAY 1862864) in Relapsed/Refractory CD22-Positive Non-Hodgkin Lymphoma: A First-in-Human, Phase I Study. Cancer Biother Radiopharm 2021;
    CrossrefPubMedSearch in Google Scholar
  • 32 Kratochwil C, Giesel FL, Bruchertseifer F, Mier W, Apostolidis C, Boll R. et al. (2)(1)(3)Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging 2014; 41 (11) 2106-2119
    CrossrefPubMedSearch in Google Scholar
  • 33 Kratochwil C, Apostolidis L, Rathke H, Apostolidis C, Bicu F, Bruchertseifer F. et al. Dosing (225)Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity. Eur J Nucl Med Mol Imaging 2021;
    CrossrefPubMedSearch in Google Scholar
  • 34 Hallqvist A, Bergmark K, Back T, Andersson H, Dahm-Kahler P, Johansson M. et al. Intraperitoneal alpha-Emitting Radioimmunotherapy with (211)At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations. J Nucl Med 2019; 60 (08) 1073-1079
    CrossrefPubMedSearch in Google Scholar
  • 35 Meredith RF, Torgue JJ, Rozgaja TA, Banaga EP, Bunch PW, Alvarez RD. et al. Safety and Outcome Measures of First-in-Human Intraperitoneal alpha Radioimmunotherapy With 212Pb-TCMC-Trastuzumab. Am J Clin Oncol 2018; 41 (07) 716-721
    CrossrefPubMedSearch in Google Scholar
  • 36 Autenrieth ME, Seidl C, Bruchertseifer F, Horn T, Kurtz F, Feuerecker B. et al. Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: a pilot study. Eur J Nucl Med Mol Imaging 2018; 45 (08) 1364-1371
    CrossrefPubMedSearch in Google Scholar
  • 37 Krolicki L, Bruchertseifer F, Kunikowska J, Koziara H, Krolicki B, Jakucinski M. et al. Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with (213)Bi-substance P analogue. Eur J Nucl Med Mol Imaging 2018; 45 (09) 1636-1644
    CrossrefPubMedSearch in Google Scholar
  • 38 Krolicki L, Bruchertseifer F, Kunikowska J, Koziara H, Pawlak D, Kulinski R. et al. Dose escalation study of targeted alpha therapy with [(225)Ac]Ac-DOTA-substance P in recurrence glioblastoma – safety and efficacy. Eur J Nucl Med Mol Imaging 2021;
    CrossrefPubMedSearch in Google Scholar
  • 39 Hammer S, Hagemann UB, Zitzmann-Kolbe S, Larsen A, Ellingsen C, Geraudie S. et al. Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer. Clin Cancer Res 2020; 26 (08) 1985-1996
    CrossrefPubMedSearch in Google Scholar
  • 40 van der Doelen MJ, Mehra N, van Oort IM, Looijen-Salamon MG, Janssen MJR, Custers JAE. et al. Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with (225)Ac-PSMA-617 targeted alpha-radiation therapy. Urol Oncol 2020;
    CrossrefPubMedSearch in Google Scholar
  • 41 Rathke H, Bruchertseifer F, Kratochwil C, Keller H, Giesel FL, Apostolidis C. et al. First patient exceeding 5-year complete remission after (225)Ac-PSMA-TAT. Eur J Nucl Med Mol Imaging 2021; 48 (01) 311-312
    CrossrefPubMedSearch in Google Scholar
  • 42 Zacherl MJ, Gildehaus FJ, Mittlmeier L, Boning G, Gosewisch A, Wenter V. et al. First Clinical Results for PSMA-Targeted alpha-Therapy Using (225)Ac-PSMA-I&T in Advanced-mCRPC Patients. J Nucl Med 2021; 62 (05) 669-674
    CrossrefPubMedSearch in Google Scholar
  • 43 Kratochwil C, Giesel FL, Heussel CP, Kazdal D, Endris V, Nientiedt C. et al. Patients Resistant Against PSMA-Targeting alpha-Radiation Therapy Often Harbor Mutations in DNA Damage-Repair-Associated Genes. J Nucl Med 2020; 61 (05) 683-688
    CrossrefPubMedSearch in Google Scholar